Fiche société
Teva Branded Pharmaceutical Products R&D, Inc.
Traitements, essais et publications liés.
Traitements3programmes
Essais3liés
Publications0liées
SourceDBlocale
Traitements
3| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| LBR-101 High DoseThe purpose of this study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in subjects with high frequency episodic migraine. | Migraine | Phase 2 | À vérifier | United States | À vérifier |
| LBR-101 Low DoseThe purpose of this study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in subjects with high frequency episodic migraine. | Migraine | Phase 2 | À vérifier | United States | À vérifier |
| LBR-101 High DoseThe purpose of this study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in subjects with high frequency episodic migraine. | Migraine | Phase 2 | À vérifier | United States | À vérifier |
Essais cliniques
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Fremanezumab | Migraine | Phase 3 | NCT04464707 | A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age | COMPLETED |
| Fremanezumab | Migraine | Phase 3 | NCT04458857 | A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age | COMPLETED |
| LBR-101 High Dose | Migraine | Phase 2 | NCT02025556 | A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine | COMPLETED |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||